Document is current
Any future updates will be listed below
-
Authors
Peng, Xiyu https://orcid.org/0000-0003-4232-0910
Smithy, James W.
Yosofvand, Mohammad
Kostrzewa, Caroline E.
Bleile, MaryLena
Ehrich, Fiona D. https://orcid.org/0000-0002-2245-9352
Lee, Jasme
Postow, Michael A. https://orcid.org/0000-0002-3367-7961
Callahan, Margaret K.
Panageas, Katherine S.
Shen, Ronglai https://orcid.org/0000-0001-9694-584X
-
Funding
Funding for this research was provided by:
Society of Memorial Sloan Kettering
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA276286)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA276286)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA276286)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA008748)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA276286)
V Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 24 October 2024
Accepted: 3 July 2025
First Online: 18 July 2025
Competing interests
: J.W.S.: Research funding—IO Biotech (Inst), Regeneron (Inst), Daiichi Sankyo (Inst); Consulting or advisory role—IO Biotech, Iovance, Bristol Myers Squibb, Daiichi Sankyo; Travel—Immatics; M.A.P.: Consulting or Advisory Role—Bristol-Myers Squibb; Cancer Expert Now; Chugai Pharma; Eisai; Erasca, Inc; Intellisphere; Merck; MJH Associates; Nektar; Novartis; Pfizer; WebMD; Research Funding—Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst); K.S.P. Stock ownership in 23 and Me, Vincerx, Eyepoint, and Kyverna; C.E.K.: Stock ownership in Johnson & Johnson; M.K.C.: BMS—Research support (Inst), advisory role/consulting; Medimmune—advisory role/consulting; Immunocore—advisory role/consulting; Merus—family member employee; M.B.: Regeneron—collaborator; Sanofi—direct contractor; X.P., J.L., M.Y., R.S., and F.D.E.: No disclosures;
